ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRTC Puretech Health Plc

129.20
2.00 (1.57%)
Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 1.57% 129.20 421,660 16:35:19
Bid Price Offer Price High Price Low Price Open Price
128.40 130.00 130.80 126.00 126.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Home Health Care Services USD 157.6M USD 53.51M USD 0.2235 5.76 304.54M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:19 O 1,121 202.00 GBX

Puretech Health (PRTC) Latest News

Puretech Health (PRTC) Discussions and Chat

Puretech Health Forums and Chat

Date Time Title Posts
11/6/202514:46PureTech Health - innovative healthcare3,149
22/7/201821:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech Health (PRTC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Puretech Health (PRTC) Top Chat Posts

Top Posts
Posted at 22/6/2025 09:20 by Puretech Health Daily Update
Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 127.20p.
Puretech Health currently has 239,421,312 shares in issue. The market capitalisation of Puretech Health is £308,374,650.
Puretech Health has a price to earnings ratio (PE ratio) of 5.76.
This morning PRTC shares opened at 126p
Posted at 30/4/2025 08:27 by the shuffle man
The Board recognizes that there remains a disconnect between the value of PureTech's assets and our share price. We are working closely with the CEO and management team to explore all strategic options to address this gap-including recent take-private discussions-with the goal of unlocking value in a manner that is in the best interest of all shareholders.
Posted at 13/4/2025 22:05 by kingston78
The share price will soon rise to 150 p, possibly this week.
Posted at 11/4/2025 09:37 by the shuffle man
He is just repeating what we already know that there is a big disconnect between value and the share price.

If you google how to read articles behind a paywall you can find links that allow you to read these pages.
Posted at 11/4/2025 07:24 by tsmith2
it's amazing how many times the share price falls while an I is loading up?
Posted at 10/4/2025 18:24 by hatfullofsky
All just noise, BioTechs in general (and BMY specifically) getting hammered again.

Clear Mr Market is bucketing PRTC in the same "below cash" group but PRTC have a 3 year run way and 2% royalty deal, not just a pile of cash and a pipe dream.

PRTC will report either on or near BMY results around 25/04 and we already know Cobenfy is flying


08/04/25 - www.investing.com/news/analyst-ratings/goldman-sachs-cuts-bristolmyers-squibb-stock-rating-target-to-55-93CH-3972978

In other recent news, Bristol-Myers Squibb’s drug Cobenfy has shown promising prescription growth, with a 9% week-over-week increase reaching 1,573 prescriptions, according to BMO Capital Markets. Analysts at BMO expect Cobenfy to generate approximately $29 million in revenue for the first quarter of 2025, surpassing current consensus estimates by 43%. UBS analysts, maintaining a Neutral rating with a $60 price target, noted a leveling off in prescriptions but still project significant sales for Cobenfy, estimating between $18 million and $21 million for the first quarter. The UBS forecast closely aligns with consensus estimates, suggesting a successful launch compared to similar antipsychotics.



$10m revenue for BMS in final 2 months of 2025
1000 prescriptions per week end January 2025 - “launch is really off to a strong start”

Trials testing it against Alzheimer’s disease psychosis and as an adjunctive therapy for schizophrenia should produce results this year and next. Farther out, Bristol Myers is planning pivotal studies in Alzheimer’s cognition, bipolar I disorder and irritability caused by Autism spectrum disorder.

Risinger and his team have forecast the drug eventually generating close to $8 billion in annual sales.
Posted at 09/4/2025 16:34 by cool runnings
This share price action is frightening ! The management need replacing asap. Rejection of an offer that is muted to be in the region of £2, because they are lining their own pockets and now they are at all time lows trading below cash ! Someone needs to start a process to remove the board and their inept CEO
Posted at 09/4/2025 11:44 by skyship
Totally bizarre price action here. Company stuffed with cash announces an Offer may be in the offing; so the share price plunges 15-20% !!!

Got to be a BUY; but failing to see the catch...
Posted at 08/4/2025 09:05 by ashkv
I appreciate PRTC has a bloated Admin Expense nonetheless this share price needs concrete management action ASAP!!!

Or this management and complacent board should be replaced!!!
Posted at 08/4/2025 09:04 by ashkv
Bizarre reaction - PRTC Directors / Management should have if permitted by rules released the takeover price that was turned down!!!

Very very odd reaction and that a short has appeared on the register when PRTC trading close to net cash.

Has UBS come out with their analysis / target price for PRTC post being appointed PRTC's Broker?
Posted at 07/4/2025 16:50 by the shuffle man
The shares trading on the NASDAQ are currently trading at $19 +5% on the day. Can we equate this back to the UK share price. This doesnt seem to be indicating a big premium.
Puretech Health share price data is direct from the London Stock Exchange

Puretech Health Frequently Asked Questions (FAQ)

What is the current Puretech Health share price?
The current share price of Puretech Health is 129.20p
How many Puretech Health shares are in issue?
Puretech Health has 239,421,312 shares in issue
What is the market cap of Puretech Health?
The market capitalisation of Puretech Health is GBP 304.54M
What is the 1 year trading range for Puretech Health share price?
Puretech Health has traded in the range of 100.40p to 217.00p during the past year
What is the PE ratio of Puretech Health?
The price to earnings ratio of Puretech Health is 5.76
What is the cash to sales ratio of Puretech Health?
The cash to sales ratio of Puretech Health is 1.96
What is the reporting currency for Puretech Health?
Puretech Health reports financial results in USD
What is the latest annual turnover for Puretech Health?
The latest annual turnover of Puretech Health is USD 157.6M
What is the latest annual profit for Puretech Health?
The latest annual profit of Puretech Health is USD 53.51M
What is the registered address of Puretech Health?
The registered address for Puretech Health is C/O TMF GROUP, 13TH FLOOR, ONE ANGEL COURT, LONDON, EC2R 7HJ
What is the Puretech Health website address?
The website address for Puretech Health is www.puretechhealth.com
Which industry sector does Puretech Health operate in?
Puretech Health operates in the HOME HEALTH CARE SERVICES sector

Your Recent History

Delayed Upgrade Clock